120 related articles for article (PubMed ID: 23648434)
1. Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Safran H; Charpentier KP; Kaubisch A; Mantripragada K; Dubel G; Perez K; Faricy-Anderson K; Miner T; Eng Y; Victor J; Plette A; Espat J; Bakalarski P; Wingate P; Berz D; Luppe D; Martel D; Rosati K; Aparo S
Am J Clin Oncol; 2015 Feb; 38(1):1-4. PubMed ID: 23648434
[TBL] [Abstract][Full Text] [Related]
2. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Shao YY; Chen BB; Ou DL; Lin ZZ; Hsu CH; Wang MJ; Cheng AL; Hsu C
Aliment Pharmacol Ther; 2017 Oct; 46(8):722-730. PubMed ID: 28815645
[TBL] [Abstract][Full Text] [Related]
4. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
Chen SW; Lin LC; Kuo YC; Liang JA; Kuo CC; Chiou JF
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1041-7. PubMed ID: 24661657
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
9. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
[TBL] [Abstract][Full Text] [Related]
10. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Ou DL; Chang CJ; Jeng YM; Lin YJ; Lin ZZ; Gandhi AK; Liao SC; Huang ZM; Hsu C; Cheng AL
J Gastroenterol Hepatol; 2014 Dec; 29(12):2021-31. PubMed ID: 25160036
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.
Dhooge M; Coriat R; Mir O; Perkins G; Brezault C; Boudou-Rouquette P; Goldwasser F; Chaussade S
Oncology; 2013; 84(1):32-8. PubMed ID: 23076239
[TBL] [Abstract][Full Text] [Related]
15. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Santini D; Addeo R; Vincenzi B; Calvieri A; Montella L; Silletta M; Caraglia M; Vespasiani U; Picardi A; Del Prete S; Tonini G
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1283-8. PubMed ID: 23094801
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
17. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]